ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Prognostic Value of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL.Frontiers in immunology · 2026Pooled it
- Mapping the research landscape of PET/CT in lymphoma: insights from a bibliometric analysis.Frontiers in oncology · 2025Pooled it
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma.La Radiologia medica · 2026Article
- Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.Blood advances · 2026Review
- Mediastinal Ectopic Pancreas Mimicking Lymphoma with Discordant Histology and Flow Cytometry: A Diagnostic Challenge.Diagnostics (Basel, Switzerland) · 2026Article
- Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response.Haematologica · 2025Article
- Prognostic value of interim [European radiology · 2025Article
- Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma withCurrent oncology (Toronto, Ont.) · 2025Article
- Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.BMC cancer · 2024Article
- Real-world applicability of the International Metabolic Prognostic Index in DLBCL: a validation cohort study.Blood advances · 2024Article
- PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Semiquantitative 2-[Frontiers in medicine · 2024Review
- Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma.Clinical and experimental medicine · 2023Article
- Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.Nature reviews. Clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Early identification of patients with diffuse large B-cell lymphoma (DLBCL) who are likely to experience disease recurrence or refractory disease after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) would be useful for improving risk-adapted treatment strategies. We aimed to assess the prognostic value of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.